WINT - Dosing underway in Windtree's mid-stage lucinactant COVID-19 trial

Biotechnology and medical device company Windtree Therapeutics (WINT) has dosed the first patient in its Phase 2 trial studying lucinactant in acute lung injury in adults with COVID-19 associated lung injury and acute respiratory distress syndrome ((ARDS)).Lucinactant is a synthetic KL4 surfactant that is structurally similar to human pulmonary surfactant.The 20-subject study will establish dosing regimen, tolerability, and functional changes in gas exchange and lung compliance after KL4 surfactant administration.Recruitment is expected to take 3-6 months for the initial trial. If the trial is successful, Windtree may initiate two further studies for lucinactant.Windtree says Lucinactant may have the potential to improve respiratory parameters and reduce the time a patient spends on mechanical ventilation and the number of days a patient spends in the intensive care unit, among other things.Windtree shares up ~6% premarket

For further details see:

Dosing underway in Windtree's mid-stage lucinactant COVID-19 trial